Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other financing activities (2020 - 2023)

Historic Other financing activities for Xeris Biopharma Holdings (XERS) over the last 4 years, with Q4 2023 value amounting to $1.2 million.

  • Xeris Biopharma Holdings' Other financing activities rose 187500.0% to $1.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.2 million, marking a year-over-year decrease of 7569.73%. This contributed to the annual value of $1.2 million for FY2023, which is 7569.73% down from last year.
  • As of Q4 2023, Xeris Biopharma Holdings' Other financing activities stood at $1.2 million, which was up 187500.0% from $60000.0 recorded in Q4 2022.
  • In the past 5 years, Xeris Biopharma Holdings' Other financing activities ranged from a high of $4.4 million in Q1 2022 and a low of $54000.0 during Q2 2021
  • For the 4-year period, Xeris Biopharma Holdings' Other financing activities averaged around $881714.3, with its median value being $159000.0 (2022).
  • Per our database at Business Quant, Xeris Biopharma Holdings' Other financing activities skyrocketed by 45000.0% in 2022 and then soared by 187500.0% in 2023.
  • Quarter analysis of 4 years shows Xeris Biopharma Holdings' Other financing activities stood at $57000.0 in 2020, then dropped by 5.26% to $54000.0 in 2021, then increased by 11.11% to $60000.0 in 2022, then surged by 1875.0% to $1.2 million in 2023.
  • Its Other financing activities was $1.2 million in Q4 2023, compared to $60000.0 in Q4 2022 and $159000.0 in Q3 2022.